Schizophrenia

Predictors of response in a sample of treatment-resistant psychotic patients on clozapine.

Ciapparelli A, Ducci F, Carmassi C, Carlini M, Paggini R, Catena M, et al. Predictors of response in a sample of treatment-resistant psychotic patients on clozapine. Eur Arch Psychiatry Clin Neurosci. 2004;254(5):343-6. DOI: 10.1007/s00406-004-0511-4. PubMed PMID: 15365711.

Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine.

Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry. 2000;47(3):252-66. PubMed PMID: 10682223.

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19(2):123-32. DOI: 10.1016/S0893-133X(98)00007-4. PubMed PMID: 9629566.

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.

Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 1996;153(8):1092-4. PubMed PMID: 8678181.

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response.

Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett. 2000;280(1):65-8. PubMed PMID: 10696813.

Genetic predictors of therapeutic response to clozapine: current status of research.

Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs. 2002;16(5):317-24. PubMed PMID: 11994021.

Risk factors for neuroleptic malignant syndrome. A case-control study.

Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989;46(10):914-8. PubMed PMID: 2572206.

Neuroleptic malignant syndrome and clozapine monotherapy.

Chatterton R, Cardy S, Schramm TM. Neuroleptic malignant syndrome and clozapine monotherapy. Aust N Z J Psychiatry. 1996;30(5):692-3. DOI: 10.3109/00048679609062668. PubMed PMID: 8902179.

An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge.

Goates MG, Escobar JI. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge. J Clin Psychopharmacol. 1992;12(2):139-40. PubMed PMID: 1573039.

Neuroleptic malignant syndrome associated with clozapine treatment.

Tsai G, Crisostomo G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry. 1995;7(2):91-5. PubMed PMID: 8556099.